A Phase III Clinical Trial for Efficacy, Immunogenicity, Safety and Immune Persistence of Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children Aged From 6-15 Years Old.

Trial Profile

A Phase III Clinical Trial for Efficacy, Immunogenicity, Safety and Immune Persistence of Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children Aged From 6-15 Years Old.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Helicobacter pylori vaccine (Primary)
  • Indications Helicobacter pylori infections
  • Focus Therapeutic Use
  • Sponsors Wuhu Kangwei Biological Technology
  • Most Recent Events

    • 03 Sep 2015 New trial record
    • 02 Jul 2015 Results published online in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top